Dacomitinib Medical Insurance Reimbursement 2023

Dacomitinib (Dacomitinib) is a prescription drug used to treat non-small cell lung cancer that has spread to other parts of the body (metastasize). Dacomitinib is used as the first treatment if the tumor has certain types of abnormal epidermal growth factor receptor (EGFR) genes. The original drug of dacomitinib has been marketed in China and has entered the scope of Class B medical insurance, but it is only reimbursed for patients who meet the indications. The reimbursement ratio is different in different regions, and the price after the application may be different. The price of a common specification of 15mg*30 tablets per box may be more than 1,000 yuan. Please consult the local medical insurance bureau or pharmacy for details.